SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2019 / Hagens Berman reminds investors in Oasmia Pharmaceutical AB (NASDAQ:OASM) of the September 27, 2019 lead plaintiff deadline in a federal ...
NEW YORK, NY / ACCESSWIRE / September 6, 2019 / Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Oasmia Pharmaceutical AB (OASM) from ...
Oasmia Pharmaceutical AB (publ) (OASM) - 20-F/A - Amended Annual and Transition Report (foreign private issuer) SEC FilingsWed, Apr. 11, 2018 ...
SAN DIEGO & UPPSALA, Sweden--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Oasmia Pharmaceutical AB (NYSE: OASM) filed a class action complaint for ...
NEW YORK, NY –November 5, 2015 – Oasmia Pharmaceutical AB (NASDAQ: OASM), is a specialty pharmaceutical company focused on innovative treatments within human and animal oncology ("Oasmia" or the ...
NEW YORK, NY –October 23, 2015 – Oasmia Pharmaceutical AB (NASDAQ: OASM), is a specialty pharmaceutical company focused on innovative treatments within human and animal oncology ("Oasmia" or the ...
Positive SPX 5,983.99 Positive IXIC 19,281.40 Positive DJI 43,910.98 trading lower Negative STOXX 500.31-0.38%Negative trading lower Negative FTSE 8,024.44-0.02%Negative trading lower Negative N225 38 ...
Julian Aleksov is Co-Founder and Executive Chairman of Oasmia Pharmaceutical AB. Mr. Aleksov co-founded Oasmia Pharmaceutical AB in 1999 and has been its Executive Chairman since May 2015 and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results